NEOVASCULAR AGE RELATED MACULAR DEGENERATION (NAMD): THE EFFECT OF AFLIBERCEPT TREATMENT ON CHOROIDAL THICKNESS IN REFRACTORY NAMD PATIENTS

被引：0
|
作者：
Wijeyakumar, Wijeyanthy [1 ,2 ]
Syed, Adil [1 ,2 ]
Hong, Thomas [1 ,2 ]
Broadhead, Geoffrey K. [1 ,2 ]
Zhu, Meidong [2 ,3 ]
Chang, Andrew A. [1 ,2 ]
机构：
[1] Sydney Retina Clin & Day Surg, Sydney, NSW, Australia
[2] Sydney Inst Vis Sci, Sydney, NSW, Australia
[3] Univ Sydney, Save Sight Inst, Sydney, NSW 2006, Australia
来源：
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY | 2014年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
121
引用
收藏
页码：124 / 125
页数：2
相关论文
共 50 条
  • [31] AFLIBERCEPT FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Verner-Cole, E. A.
    Davis, S. J.
    Lauer, A. K.
    DRUGS OF TODAY, 2012, 48 (05) : 317 - 329
  • [32] A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom
    Johnston, Robert L.
    Carius, Hans-Joachim
    Skelly, Adrian
    Ferreira, Alberto
    Milnes, Fran
    Mitchell, Paul
    ADVANCES IN THERAPY, 2017, 34 (03) : 703 - 712
  • [33] Real-world rapid mean visual acuity improvement in patients initiated on aflibercept therapy for treatment-naive neovascular age-related macular degeneration (nAMD)
    Crosby-Nwaobi, Roxanne R.
    Hykin, Philip G.
    Sivaprasad, Sobha
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [34] Real -world outcomes of faricimab injections in treatment -na ve neovascular age -related macular degeneration (nAMD) patients: The Moorfields Experience
    Sim, Sing Yue
    Nicholson, Luke
    Patel, Praveen J.
    Bhatia, Bhairavi
    Chalkiadaki, Evangelia
    Koutsocheras, Georgios
    Selvam, Senthil
    Sivaprasad, Sobha
    Pal, Bishwanath
    Keane, Pearse Andrew
    Hamilton, Robin
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [35] Impact on clinic capacity of using aflibercept for neovascular age related macular degeneration (nAMD) in year 2 in Calderdale and Huddersfield NHS Foundation Trust
    Ibrahim, A. A. H.
    Hashmani, K.
    Blizzard, R. M.
    Chen, Y.
    Lane, M.
    Khan, R. S.
    EYE, 2017, 31 : S11 - S11
  • [36] Correlation of Sdoct-Morphology and Retinal Function in Neovascular Age-Related Macular Degeneration (namd)
    Sulzbacher, F.
    Kiss, C. G.
    Munk, M.
    Eisenkoelbl, S.
    Sacu, S.
    Schmidt-Erfurth, U.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [37] Long-term anatomical and functional outcomes in patients with neovascular age-related macular degeneration (nAMD) after switching from Ranibizumab to Aflibercept therapy
    Christou, Louise
    Kirthi, Varo
    Peregrine, Helen
    Essaji, Fariha
    Canning, Sarah
    Ioannidis, Pantelis
    Kashani, Shahram
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [38] COST-MINIMIZATION OF FARICIMAB VS AFLIBERCEPT 8 MG IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD): EVALUATING THE IMPACT OF RETREATMENT CRITERIA
    Buhrer, C.
    Bagijn, M.
    Fasci, A.
    Cox, O.
    VALUE IN HEALTH, 2024, 27 (12)
  • [39] A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom
    Robert L. Johnston
    Hans-Joachim Carius
    Adrian Skelly
    Alberto Ferreira
    Fran Milnes
    Paul Mitchell
    Advances in Therapy, 2017, 34 : 703 - 712
  • [40] Two Year Real World Outcomes of Ranibizumab Therapy for Neovascular Age Related Macular Degeneration (nAMD)
    Bhalla, Minak
    Muniraju, Ramu
    OPHTHALMOLOGICA, 2014, 232 : 4 - 4
12345